Drugs / JTT-662
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04465877 | Jun 2020 → Feb 2021 | type 2 diabetes mellitus | Akros Pharma Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTT-662 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04465877 ↗ |
| Route | Oral | “JTT-662 5 mg orally once daily from Day 1 to Day 28” NCT04465877 ↗ |